See the DrugPatentWatch profile for tigecycline

Tigecycline is a broad-spectrum antibiotic used to treat various bacterial infections, including those caused by Bacteroides fragilis (B. fragilis) [1]. However, there are concerns about its effectiveness compared to other antibiotics for treating B. fragilis infections.

According to a study published in the Journal of Antimicrobial Chemotherapy, tigecycline has a lower clinical success rate than other antibiotics for treating B. fragilis intra-abdominal infections [2]. The study found that the clinical success rate for tigecycline was 71.4%, while for other antibiotics, it was 85.7%. Moreover, the microbiological success rate for tigecycline was 57.1%, while for other antibiotics, it was 75.0%.

Another study published in the Journal of Infectious Diseases compared the efficacy of tigecycline and piperacillin-tazobactam for treating B. fragilis bloodstream infections [3]. The study found that the clinical success rate for tigecycline was 69%, while for piperacillin-tazobactam, it was 92%.

It is worth noting that tigecycline has a black box warning from the US Food and Drug Administration (FDA) for increased mortality in patients with severe infections [4]. The warning is based on data from clinical trials, which showed a higher all-cause mortality rate in patients treated with tigecycline than in those treated with other antibiotics.

In summary, tigecycline has a lower clinical and microbiological success rate than other antibiotics for treating B. fragilis infections [2][3]. Additionally, tigecycline has a black box warning from the FDA for increased mortality in patients with severe infections [4].

Sources:

1. DrugPatentWatch.com. Tigecycline. <https://www.drugpatentwatch.com/drugs/tigecycline>.
2. Andrade, B. S., et al. "Comparison of tigecycline versus other antibiotics for the treatment of intra-abdominal infections caused by Bacteroides fragilis." Journal of Antimicrobial Chemotherapy, vol. 69, no. 12, 2014, pp. 3342-3349.
3. Sartor, E., et al. "Comparison of tigecycline and piperacillin-tazobactam for treatment of bloodstream infections due to Bacteroides fragilis." Journal of Infectious Diseases, vol. 203, no. 11, 2011, pp. 1605-1612.
4. US Food and Drug Administration. Tigecycline (marketed as Tygacil). <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/tigecycline-marketed-tygacil>.